Sautner D, Saeger W, Lüdecke DW (1993) Tumors of the Sellar region mimicking pituitary adenomas. Exp Clin Endocrinol Diabetes 101(05):283–289

Article  CAS  Google Scholar 

Clayton RN (1999) Sporadic pituitary tumours: from epidemiology to use of databases. Best Pract Res Clin Endocrinol Metab 13(3):451–460

Article  CAS  Google Scholar 

Colao A (2009) The prolactinoma. Best Pract Res Clin Endocrinol Metab 23(5):575–596

Article  CAS  PubMed  Google Scholar 

Pinzone JJ, Katznelson L, Danila DC, Pauler DK, Miller CS, Klibanski A (2000) Primary medical therapy of micro-and macroprolactinomas in men. J Clin Endocrinol Metabolism 85(9):3053–3057

CAS  Google Scholar 

Mindermann T, Wilson CB (1994) Age-related and gender‐related occurrence of pituitary adenomas. Clin Endocrinol 41(3):359–364

Article  CAS  Google Scholar 

Vaneckova M, Seidl Z, Hana V, Jarkovska Z (2007) Macroprolactinomas: retrospective follow up study in the MR imaging and correlation with clinical symptomatology. Neuroendocrinol Lett 28(6):841–845

PubMed  Google Scholar 

Klibanski A, Zervas NT (1991) Diagnosis and management of hormone-secreting pituitary adenomas. N Engl J Med 324(12):822–831

Article  CAS  PubMed  Google Scholar 

Vilar L, Freitas MC, Naves LA, Casulari LA, Azevedo M, Montenegro R, Bronstein MD (2008) Diagnosis and management of hyperprolactinemia: results of a Brazilian multicenter study with 1234 patients. J Endocrinol Investig 31(5):436–444

Article  CAS  Google Scholar 

Colao A, Somma CD, Lombardi G, Pivonello R, Sarno AD (2002) Dopamine receptor agonists for treating prolactinomas. Expert Opin Investig Drugs 11(6):787–800

Article  CAS  PubMed  Google Scholar 

Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R, Colao A (2001) Resistance to Cabergoline as compared with Bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metabolism 86(11):5256–5261

Article  Google Scholar 

Gillam MP, Molitch ME, Lombardi G, Colao A (2006) Advances in the treatment of prolactinomas. Endocr Rev 27(5):485–534

Article  CAS  PubMed  Google Scholar 

Kars M, Pereira AM, Bax JJ, Romijn JA (2008) Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required. Eur J Endocrinol 159(4):363

Article  CAS  PubMed  Google Scholar 

Greenman Y, Tordjman K, Stern N (1998) Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels. Clin Endocrinol 48(5):547–553

Article  CAS  Google Scholar 

Goede DL, Hauser RS (2006) Increased prevalence of high Body Mass Index in patients presenting with pituitary tumours: severe obesity in patients with macroprolactinoma. Swiss medical weekly, 136(1516)

Al Sabie F, Tariq Z, Erickson D, Donegan D (2021) Association between prolactinoma and body mass index. Endocr Pract 27(4):312–317

Article  PubMed  Google Scholar 

Pereira-Lima JFS, Leães CGS, Neto FMF, Barbosa MV, Silva AL, Oliveira MD (2013) Hyperprolactinemia and body weight: prevalence of obesity and overweight in patients with hyperprolactinemia. Res J Endocrinol Metab 1(1):2

Article  Google Scholar 

Doknic M, Pekic S, Zarkovic M, Medic-Stojanoska M, Dieguez C, Casanueva F, Popovic V (2002) Dopaminergic tone and obesity: an insight from prolactinomas treated with Bromocriptine. Eur J Endocrinol 147(1):77–84

Article  CAS  PubMed  Google Scholar 

Southon A, Walder K, Sanigorski AM, Zimmet P, Nicholson GC, Kotowicz MA, Collier G (2003) The Taq IA and Ser311 Cys polymorphisms in the dopamine D2 receptor gene and obesity. Diabetes Nutr Metab 16(1):72–76

CAS  PubMed  Google Scholar 

Athanasoulia AP, Sievers C, Uhr M, Ising M, Stalla GK, Schneider HJ (2014) The effect of the ANKK1/DRD2 Taq1A polymorphism on weight changes of dopaminergic treatment in prolactinomas. Pituitary 17(3):240–245

Article  CAS  PubMed  Google Scholar 

Pirchio R, Graziadio C, Colao A, Pivonello R, Auriemma RS (2022) Metabolic effects of prolactin. Front Endocrinol 13:1015520

Article  Google Scholar 

Kirsch P, Kunadia J, Shah S, Agrawal N (2022) Metabolic effects of prolactin and the role of dopamine agonists: A review. Front Endocrinol 13:1002320

Article  Google Scholar 

Chien HY, Chen SM, Li WC (2023) Dopamine receptor agonists mechanism of actions on glucose Lowering and their connections with prolactin actions. Front Clin Diabetes Healthc 4:935872

Article  PubMed  PubMed Central  Google Scholar 

Ali M, Mirza L (2021) Morbid obesity due to prolactinoma and significant weight loss after dopamine agonist treatment. AACE Clin Case Rep 7(3):204–206

Article  CAS  PubMed  PubMed Central  Google Scholar 

Berinder K, Nyström T, Höybye C, Hall K, Hulting AL (2011) Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy. Pituitary 14(3):199–207

Article  CAS  PubMed  Google Scholar 

Pala NA, Laway BA, Misgar RA, Dar RA (2015) Metabolic abnormalities in patients with prolactinoma: response to treatment with Cabergoline. Diabetol Metab Syndr 7(1):1–6

Article  Google Scholar 

Byberg S, Futtrup J, Andreassen M, Krogh J (2019) Metabolic effects of dopamine agonists in patients with prolactinomas: a systematic review and meta-analysis. Endocr Connections 8(10):1395–1404

Article  CAS  Google Scholar 

Santos-Silva CM, Barbosa FR, Lima GA, Warszawski L, Fontes R, Domingues RC, Gadelha MR (2011) BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity 19(4):800–805

Article  PubMed  Google Scholar 

Gibson CD, Karmally W, McMahon DJ, Wardlaw SL, Korner J (2012) Randomized pilot study of Cabergoline, a dopamine receptor agonist: effects on body weight and glucose tolerance in obese adults. Diabetes Obes Metabolism 14(4):335–340

Article  CAS  Google Scholar 

Soran H, Wilding J, MacFarlane I (2004) Body weight and prolactinoma: a retrospective study. Int J Obes 28(1):183–183

Article  CAS  Google Scholar 

Yermus R, Ezzat S (2002) Does normalization of prolactin levels result in weight loss in patients with prolactin secreting pituitary adenomas? Clin Endocrinol 56(4):562–562

Article  CAS  Google Scholar 

Delgrange E, Donckier J, Maiter D (1999) Hyperprolactinaemia as a reversible cause of weight gain in male patients? Clin Endocrinol 50(2):271

Article  CAS  Google Scholar 

Ben-Jonathan N, Hnasko R (2001) Dopamine as a prolactin (PRL) inhibitor. Endocr Rev 22(6):724–763

Article  CAS  PubMed  Google Scholar 

Wang GJ, Volkow ND, Logan J, Pappas NR, Wong CT, Zhu W,… Fowler,JS (2001). Brain dopamine and obesity. The Lancet, 357(9253), 354–357.

Shibli-Rahhal A, Schlechte J (2009) The effects of hyperprolactinemia on bone and fat. Pituitary 12(2):96–104

Article  CAS  PubMed  Google Scholar 

Bina KG, Cincotta AH (2000) Dopaminergic agonists normalize elevated hypothalamic neuropeptide Y and corticotropin-releasing hormone, body weight gain, and hyperglycemia in Ob/ob mice. Neuroendocrinology 71(1):68–78

Article  CAS  PubMed  Google Scholar 

Cincotta AH, Meier AH (1989) Reductions of body fat stores and total plasma cholesterol and triglyceride concentrations in several species by Bromocriptine treatment. Life Sci 45(23):2247–2254

Article  CAS  PubMed  Google Scholar 

Folgueira, C., Beiroa, D., Porteiro, B., Duquenne, M., Puighermanal, E., Fondevila,M. F.,… Nogueiras, R. (2019). Hypothalamic dopamine signalling regulates brown fat thermogenesis. Nature metabolism, 1(8), 811–829.

Ling C, Svensson L, Odén B, Weijdegård B, Edén B, Edén S, Billig H (2003) Identification of functional prolactin (PRL) receptor gene expression: PRL inhibits lipoprotein lipase activity in human white adipose tissue. J Clin Endocrinol Metabolism 88(4):1804–1808

Article